Knowledge pages
Entity-grounded reference for genes, proteins, mechanisms, diseases, drugs, phenotypes, and SciDEX itself. Every page links back into the knowledge graph.
Showing investment pages.
Wnt Signaling Therapeutics: Investment Landscape Analysis
investment**Wnt Signaling Therapeutics: Investment Landscape Analysis** covers the current R&D investment, clinical trial pipeline, and funding trends for Wnt signaling-based therapies in neurodegenerative . [@wnt2024] *Last updat…
investment-wnt-signalingViral Vector Delivery Investment Landscape for Neurodegeneration
investmentViral vector delivery represents one of the most critical enabling technologies for gene therapy approaches to neurodegenerative diseases. The global market for viral vectors in CNS gene therapy is experiencing rapid gro…
investment-viral-vector-delivery-gene-therapyVascular Dementia Investment Landscape
investment**Investment Landscape: Vascular Dementia** covers the current R&D investment, clinical trial pipeline, and funding trends for Vascular Dementia (VaD) research. *Last updated: 2026-03-22 03:00 PT* --- **Total Clinical Tr…
investment-vascular_dementiaUbiquitin-Proteasome System (UPS) Therapeutics: Investment Landscape Analysis
investmentThe [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system) (UPS) represents a critical therapeutic target for neurodegenerative disease drug development[@ubiquitinproteasome2023]. As the primary intracell…
investment-ups-therapeuticsTREM2 Therapeutics Investment Landscape
investmentTREM2 (Triggering Receptor Expressed on Myeloid Cells 2) represents one of the most significant therapeutic targets in neurodegenerative disease drug development. Genetic evidence strongly links TREM2 variants to Alzheim…
investment-trem2-therapeutics-landscapeTGF-beta Signaling Therapeutics for Neurodegeneration: Investment Analysis
investmentTGF-beta Signaling Therapeutics for Neurodegeneration: Investment Analysis is a therapeutic candidate being investigated for the treatment of neurodegenerative diseases. This page provides comprehensive information on it…
investment-tgf-beta-signaling-therapeutics-investment-analysisTDP-43 Proteinopathy Investment Landscape
investmentThis page summarizes trial-derived R&D investment signals for TDP-43 proteinopathy therapeutics, primarily focused on [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis) and [Frontotemporal Dem…
investment-tdp-43-proteinopathyTau Aggregation Inhibitors — Investment Landscape Analysis
investment[Tau aggregation inhibitors](/therapeutics/tau-aggregation-inhibitors) represent a critical therapeutic approach for Alzheimer's disease and related tauopathies. This investment landscape analysis examines the current pi…
investment-tau-aggregation-inhibitorsSynaptic Dysfunction Therapeutics: Investment Landscape Analysis
investmentSynaptic dysfunction represents one of the earliest and most critical pathological features in neurodegenerative diseases, yet therapeutic targeting of synaptic protection and restoration remains significantly underinves…
investment-synaptic-dysfunctionStem Cell Therapy Investment Landscape for Neurodegeneration
investmentStem cell therapy represents a promising approach for neurodegenerative disease treatment, with potential for cell replacement, trophic support, and immunomodulation. This investment landscape analyzes the current state…
investment-stem-cell-therapy-neurodegenerationInvestment Landscape: Sirtuin Therapeutics for Neurodegeneration
investmentSirtuins (SIRT1-7) are NAD+-dependent deacetylases that have emerged as promising therapeutic targets for neurodegenerative diseases. The investment landscape has evolved significantly, with focus shifting between SIRT1…
investment-sirtuin-therapeutics-neurodegenerationSenolytic Therapeutics: Investment Landscape Analysis
investmentThis page provides investment landscape analysis for senolytic and senostatic therapeutics targeting neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and related conditions. The a…
investment-senolytic-therapeuticsRNA Therapeutics for Neurodegeneration Investment Landscape
investmentRNA therapeutics represent one of the most promising and rapidly evolving modalities for treating neurodegenerative diseases. This investment landscape analysis examines the current funding environment, technological app…
investment-rna-therapeutics-neurodegenerationRNA Therapeutics: Investment Landscape Analysis
investment**Investment Landscape: RNA-Based Therapeutics** covers the current R&D investment, clinical trial pipeline, and funding trends for RNA-based therapeutic approaches in neurodegenerative diseases including Alzheimer's Dis…
investment-rna-therapeuticsInvestment Rankings
investmentThis page ranks therapeutic investment opportunities in neurodegenerative disease research by various criteria including market opportunity, pipeline strength, clinical trial activity, and mechanistic novelty. These rank…
investment-rankingsPyroptosis Inhibitors for Neurodegeneration — Investment Landscape Analysis
investmentPyroptosis inhibition has emerged as a promising therapeutic strategy for neurodegenerative diseases, targeting the inflammatory cell death pathway that links chronic [neuroinflammation](/mechanisms/neuroinflammation) to…
investment-pyroptosis-inhibitors-neurodegenerationProgressive Supranuclear Palsy Investment Landscape
investment**Investment Landscape: Progressive Supranuclear Palsy** covers the current R&D investment, clinical trial pipeline, funding trends, and investment opportunities for Progressive Supranuclear Palsy research. *Last updated…
investment-pspProtein Kinase Inhibitors for Neurodegeneration: Investment Landscape Analysis
investmentThis page provides an investment landscape analysis of protein kinase inhibitors being developed for neurodegenerative disease treatment. Protein kinases represent one of the most druggable target families in drug develo…
investment-protein-kinase-inhibitorsProtein Aggregation Inhibitors for Neurodegeneration — Investment Landscape Analysis
investmentProtein aggregation represents one of the hallmark pathological features of neurodegenerative , with [amyloid-beta](/proteins/amyloid-beta) plaques in Alzheimer's disease, [tau](/proteins/tau) neurofibrillary tangles, [a…
investment-protein-aggregation-therapeuticsProgressive Supranuclear Palsy (PSP) Investment Landscape
investmentProgressive Supranuclear Palsy (PSP) represents a significant unmet medical need in the neurodegenerative disease space, with a current global market estimated at approximately $250 million and projected to reach $1.2 bi…
investment-progressive_supranuclear_palsyPriority Research Areas for Neurodegenerative Disease R&D
investmentThis page identifies priority research areas for neurodegenerative disease R&D, focusing on therapeutic targets, mechanistic pathways, and strategic investment opportunities. The analysis considers disease burden, scient…
investment-priority-research-areasPrion Diseases Investment Landscape
investmentThis page summarizes trial-derived R&D investment signals for Prion Diseases including Creutzfeldt-Jakob Disease (CJD), Fatal Familial Insomnia (FFI), Gerstmann-Sträussler-Scheinker Syndrome (GSS), Kuru, and Variant CJD.…
investment-prion-diseasesPeptide Therapeutics for Neurodegeneration — Investment Landscape Analysis
investmentPeptide therapeutics represent a rapidly evolving segment of the neurodegenerative disease drug development landscape. This investment analysis examines the current state of peptide-based approaches for Alzheimer's disea…
investment-peptide-therapeuticsParkinson's vs Huntington's: Comparative Investment Analysis
investmentThis page compares investment opportunities and therapeutic development strategies between Parkinson's disease (PD) and Huntington's disease (HD), two major neurodegenerative disorders with distinct pathophysiologies and…
investment-parkinsons-vs-huntingtons-comparison